A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

• by Jin-Hui Chen, Tsen-Fang Tsai

• May 2, 2026

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

• by Kathryn Wighton

• May 18, 2026

• 2 min

Spondyloarthritis function varies by sex

Women had greater functional deterioration over 17 years, while permanent work disability did not differ significantly between sexes.

• by Kathryn Wighton

• August 20, 2026

• 4 min

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

• by Kathryn Wighton

• June 29, 2026

• 3 min